Abstracts tagged "risk factors"

Abstract Number: 0215 • ACR Convergence 2024
BP Connect Improves Follow-up of High Blood Pressure in Urban Rheumatology and Non-Rheumatology Clinics
Alexa Figueroa Baiges¹, David Gazeley², Monica Messina¹, Bret Hanlon³, Edmond Ramly⁴, Ann Rosenthal⁵, Laura Stewart⁶, Makeba Williams⁷, Heidi W. Brown⁸ and Christie Bartels⁹, ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Medical College of Wisconsin, Wauwatosa, WI, ³Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Indiana University School of Public Health, Bloomington, IN, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶Froedtert and Medical College of Wisconsin, Milwaukee, WI, ⁷Washington University in St. Louis School of Medicine, St. Louis, MO, ⁸Division of Health Services Research & Implementation Science, Kaiser Permanente, San Diego, CA, ⁹University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Hypertension accounts for >54% of modifiable cardiovascular disease (CVD) risk and although 49% of US outpatient visits occur in specialty clinics, only 10% of…
Abstract Number: 0841 • ACR Convergence 2024
Clinical and Biologic Predictors of Thrombosis in Persistently Antiphospholipid Antibody Positive Patients: Prospective Analysis of the International APS ACTION Clinical Database and Repository (“Registry”)
Jonathan Thaler¹, Michael Parides¹, Danieli Andrade², Diana Paredes-Ruiz³, Maria Tektonidou⁴, Vittorio Pengo⁵, Savino Sciascia⁶, Cecilia Nalli⁷, Guilherme Ramires de Jesús⁸, Paul Fortin⁹, Maria Efthymiou¹⁰, H Michael Belmont¹¹, Michelle Petri¹², Ricard Cervera¹³, Leslie Skeith¹⁴, TATSUYA ATSUMI¹⁵, Chary Lopez-Pedrera¹⁶, Yu Zuo¹⁷, David Branch¹⁸, Rohan Willis¹⁹, Nina Kello²⁰, Zhuoli Zhang²¹, Esther Rodriguez-Almaraz²², Bahar Artim Esen²³, Jose Pardos-Gea²⁴, Guillermo Pons-Estel²⁵, Giulia Pazzola²⁶, Hui Shi¹⁷, Ali Duarte-Garcia²⁷, Medha Barbhaiya¹, Cécile Yelnik²⁸, Pierluigi Meroni²⁹, Robert Roubey³⁰, Maria Laura Bertolaccini³¹, Hannah Cohen³², Jacob Rand³³ and Doruk Erkan¹, and on behalf of APS ACTION, ¹Hospital for Special Surgery, New York, NY, ²University of São Paulo, São Paulo, SP, Brazil, ³Autoimmune Diseases Research Unit. Biocruces Bizkaia Health Research Institute, Baracaldo, Spain, ⁴National and Kapodistrian University of Athens, Athens, Greece, ⁵Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, ⁶University of Turin, Torino, Turin, Italy, ⁷ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁸Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ⁹Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹⁰University College London, London, United Kingdom, ¹¹NYU School of Medicine, New York, NY, ¹²Johns Hopkins University School of Medicine, Timonium, MD, ¹³Hospital Clinic de Barcelona, Barcelona, Spain, ¹⁴University of Calgary, Calgary, ON, Canada, ¹⁵Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ¹⁶IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ¹⁷University of Michigan, Ann Arbor, MI, ¹⁸University of Utah and Intermountain Healthcare, Salt Lake City, UT, ¹⁹University of Texas Medical Branch, Galveston, TX, ²⁰Northwell Health, Brooklyn, NY, ²¹Peking University First Hospital, Beijing, China, ²²Hospital Universitario 12 de Octubre, Madrid, Spain, ²³Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁴Vall d'Hebron University Hospital, Barcelona, Spain, ²⁵CREAR, Rosario, Argentina, ²⁶Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, ²⁷Mayo Clinic, Rochester, MN, ²⁸lille university, Lille, France, ²⁹IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, ³⁰Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, ³¹King's College London, London, United Kingdom, ³²University College London Hospitals NHS Foundation Trust, London, United Kingdom, ³³Weill Cornell Medical Center, Bronx, NY
Background/Purpose: There is a lack of high-quality data to inform risk-stratified long-term thrombosis prevention strategies in patients with persistently positive antiphospholipid antibodies (aPL). The APS…
Abstract Number: 1163 • ACR Convergence 2024
Characteristics of Interstitial Lung Disease Progressors in an Antisynthetase Autoantibody-Positive Population
Aurélie Mourot¹, Beatrice Panuta¹, Juliette Charbonneau¹, Ange Mounkam Ngeuleu¹, Caroline Vo², Eric Rich³, Josiane Bourré-Tessier³, Edith Villeneuve³, Hélène Manganas³, Andréanne Gauthier³, Julie Morisset³, Sabrina Anh-Tu Hoa³ and Océane Landon-Cardinal³, ¹University of Montreal, Montreal, QC, Canada, ²Hôpital Charles Lemoyne, Montreal, QC, Canada, ³Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada
Background/Purpose: Antisynthetase syndrome (ASSD) is characterized by interstitial lung disease (ILD), myositis, polyarthritis, Raynaud’s phenomenon, dermatomyositis-like rash and mechanic’s hands. ILD may present with isolated…
Abstract Number: 2137 • ACR Convergence 2024
Fractures Post Lung Transplant: A Retrospective Cohort Study Conducted at an International Transplant Center
Annmarie Miranda¹, Adil Vural², Chao Zhang³, Jennifer Varley⁴, Walaa Abu Alya⁵, Komal Mushtaq⁶, Marie Budev¹, Abby Abelson¹, Chad Deal⁷ and Sarah Keller¹, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Avon, OH, ³Cleveland Clinic, Cleveland Heights, OH, ⁴Heritage College of Osteopathic Medicine, Ohio University, Beachwood, OH, ⁵An-najah National University., Westlake, OH, ⁶Cleveland Clinic, Fairview Park, OH, ⁷Cleveland Clinic, Shaker Heights, OH
Background/Purpose: The incidence of fractures due to osteoporosis (OP) is increased in patients with end-stage lung disease and fractures are a well-known complication of lung…
Abstract Number: 2640 • ACR Convergence 2024
Comparative Safety and Use of Non-conventional Combination Targeted Therapy in Adults with Psoriatic Arthritis
Alexander Wu¹, Arianna Zhang², Yujia Guo¹, Jialing Liu¹, Donghan Yang¹, Lourdes Perez Chada³, Alexis Ogdie⁴, Jose Scher⁵ and Joseph Merola⁶, ¹University of Texas Southwestern Medical Center, Dallas, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Wayland, MA, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵New York University School of Medicine, New York, NY, ⁶UT Southwestern Medical Center, Newton, MA
Background/Purpose: Psoriatic arthritis is a chronic systemic inflammatory disorder with significant impacts on health and life quality. Achieving good disease control in psoriatic arthritis (PsA)…
Abstract Number: 0304 • ACR Convergence 2024
Severe Infection in COVID-19 Vaccinated Patients with Systemic Autoimmune Rheumatic Diseases on B Cell Targeted Therapies: Association with Neutrophil-lymphocyte Ratio
doryan Garcia Olivas¹, Judith Hernández Sánchez¹, luis Bausá Gimeno¹, Javier Nóvoa Medina¹, Sergio Machín¹, Maria Ángeles Acosta-Mérida¹, Diana Botello-Corzo¹, daniel Batista Perdomo¹, José Ángel Hernández Beriain² and Beatriz Tejera Segura¹, ¹Rheumatology Department. Hospital Universitario Insular de Gran Canaria, las Palmas, Spain, ²Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran C, Spain
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARDs) are at higher risk of general infection due to the presence of comorbidities, underlying disease activity, and…
Abstract Number: 0842 • ACR Convergence 2024
The Incident Risk and Predictors of Systemic Autoimmune Rheumatic Disease (SARD) Development in Persistently Antiphospholipid Antibody Positive Patients Without SARDs: Prospective Results from the APS ACTION Clinical Database and Repository (“Registry”)
Reyhan Kose Cobanoglu¹, Rohan Willis², Diana Paredes-Ruiz³, Maria G Tektonidou⁴, Vittorio Pengo⁵, Savino Sciascia⁶, Cecilia Nalli⁷, Flavio Victor Signorelli⁸, Paul Fortin⁹, Maria Efthymiou¹⁰, H Michael Belmont¹¹, Michelle Petri¹², Ricard Cervera¹³, Megan Barber¹⁴, TATSUYA ATSUMI¹⁵, Chary Lopez-Pedrera¹⁶, Jason Knight¹⁷, David Branch¹⁸, Nina Kello¹⁹, Lanlan Ji²⁰, Esther Rodriguez-Almaraz²¹, Bahar Artim Esen²², Jose Pardos Gea²³, Rosana Quintana²⁴, Giulia Pazzola²⁵, Hui Shi²⁶, Ali Duarte-Garcia²⁷, Pierluigi Meroni²⁸, Robert Roubey²⁹, Maria Laura Bertolaccini³⁰, Hannah Cohen³¹, Danieli Andrade³² and Doruk Erkan³³, and on behalf of APS ACTION, ¹Aydin Adnan Menderes University School of Medicine, Hospital for Special Surgery, NY, USA, Aydin, Turkey, ²University of Texas Medical Branch, Galveston, TX, ³Biocruces Bizkaia Health Research Institute, Bizkaia, Spain, ⁴National and Kapodistrian University of Athens, Athens, Greece, ⁵Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, ⁶University of Turin, Torino, Turin, Italy, ⁷ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁸Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ⁹Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹⁰University College London, London, United Kingdom, ¹¹NYU School of Medicine, New York, NY, ¹²Johns Hopkins University School of Medicine, Timonium, MD, ¹³Hospital Clinic de Barcelona, Barcelona, Spain, ¹⁴Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹⁵Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ¹⁶IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ¹⁷University of Michigan, Ann Arbor, MI, ¹⁸University of Utah and Intermountain Healthcare, Salt Lake City, UT, ¹⁹Northwell Health, Brooklyn, NY, ²⁰Peking University First Hospital, Peking, China (People's Republic), ²¹Hospital Universitario 12 de Octubre, Madrid, Spain, ²²Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ²³Vall d'Hebron University Hospital, Barcelona, Spain, ²⁴Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ²⁵Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, ²⁶Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China (People's Republic), ²⁷Mayo Clinic, Rochester, MN, ²⁸IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, ²⁹Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, ³⁰King's College London, London, United Kingdom, ³¹University College London Hospitals NHS Foundation Trust, London, United Kingdom, ³²University of São Paulo, São Paulo, SP, Brazil, ³³Hospital for Special Surgery, New York, NY
Background/Purpose: APS ACTION “Registry” was created to study the natural course of disease in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic autoimmune rheumatic diseases…
Abstract Number: 1345 • ACR Convergence 2024
Long-term Changes in Coronary Calcium Score Levels Among Patients with Rheumatoid Arthritis: A Cohort Study
Cristina Corrales Selaya¹, Nuria Vegas Revenga², Carmen Secada Gómez³, Jose Antonio parra-Blanco⁴, Virginia Portilla-González⁴, Ricardo Blanco-Alonso⁵, Miguel Angel Gonzalez-Gay⁶, ivan Ferraz-Amaro⁷ and alfonso Corrales-Martínez⁸, ¹Rheumatology, Marques de Valdecilla University Hospital. IDIVAL, Santander, Cantabria, Spain, ²Hospital Galdakao- Usansolo, Galdakao, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁶University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁷Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁸Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of subclinical cardiovascular (CV) disease and, consequently, a higher incidence of CV events, compared to the…
Abstract Number: 2138 • ACR Convergence 2024
DXA-derived 3D Parameters of the Hip Discriminate Prevalent Fragility Fractures in Individuals with Axial Spondyloarthritis
Edgar Wiebe¹, Elisa Schilling², Dörte Huscher², Zhivana Boydzhieva³, andriko Palmowski⁴, Sandra Hermann⁵, burkhard Muche⁵, Gerhard Krönke⁵ and FRANK HARTMUT DR. BUTTGEREIT¹, ¹Charité University Medicine Berlin, Berlin, Germany, ²Charité-Universitätsmedizin Berlin, Berlin, Germany, ³Charité Universittsmedizin, Berlin, Germany, ⁴Charité - Universittsmedizin Berlin, Berlin, Germany, ⁵Rheumatology, Charité, Berlin, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is associated with osteoporosis and fragility fracture risk that may not be reflected by areal bone mineral density (aBMD) measurements alone.…
Abstract Number: 2652 • ACR Convergence 2024
Characteristics of Relapse and Therapeutic Management in Giant Cell Arteritis in Modern Era, NEWTON Study
Geoffroy Peyrac¹, Natalie Lomba Goncalves¹, Aïcha Kante², Patrice Cacoub³, Karim Sacré⁴, David Saadoun⁵, Thomas Papo⁴, Jean-François Alexandra⁶, Valentin Pagis⁷, Venceslas Bourdin¹, Pascal Richette⁸, Arnaud Vanjak⁹, Augustin Latourte¹⁰, Dikélélé Elessa⁷, William Bigot¹, Ruxandra burlacu⁷, Karine Champion¹, Blanca Amador Borrero⁷, Amanda Lopes¹, Audrey Depond⁷, Peggy Reiner¹¹, Homa Adle-Biassette¹², Aude Couturier¹³, Philippe Bonnin¹⁴, Alexandre Boutigny¹⁵, Frédéric Paycha¹⁶, Anne Couvelard¹⁷, Alexis Régent¹⁸, Benjamin Chaigne¹⁹, Yann Nguyen²⁰, Agnès lefort²⁰, Olivier Bory²¹, Elisabeth Aslangul²², stephane mouly¹, Damien Sène¹, Viet-Thi Tran²³ and Cloé Comarmond¹, and Groupe d'étude français de l'artérite à cellules géantes (GEFA), ¹Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, ²Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Université Paris Cité, Paris, Ile-de-France, France, ³Sorbonne Université, Paris, ⁴Université Paris Cité, Paris, France, ⁵Department of internal medicine, Centre de Référence Maladies Rares autoimmunes et inflammatoires, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France, ⁶INSERM U959, Immunology-Immunopathology-Immunotherapy, Pitié-Salpêtrière Hospital, Paris, France, ⁷Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, France, ⁸Lariboisière Hospital, Paris, France, ⁹Department of Rheumatoloy, Lariboisière Hospital, Université Paris Cité, Paris, France, ¹⁰AP-HP, Paris, France, ¹¹Department of Neurology, Lariboisière Hospital, Université Paris Cité, Paris, France, ¹²Department of Pathology, Lariboisière Hospital, Université Paris Cité, Paris, France, ¹³Department of ophthalmology, Lariboisière Hospital, Université Paris Cité, Paris, France, ¹⁴Department of physiology, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, ¹⁵Department of physiology, Lariboisière Hospital, Université Paris Cité, Paris, France, ¹⁶Department of nuclear medicine, Saint-Louis Hospital, Université Paris Cité, Paris, France, ¹⁷Department of Pathology, Bichat Hospital, Université Paris Cité, Paris, Paris, Ile-de-France, France, ¹⁸National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ¹⁹Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France, ²⁰Department of Internal medicine, Beaujon Hospital, Université Paris Cité, Clichy, France, ²¹Department of internal medicine, Louis Mourier Hospital, Université Paris Cité, Colombes, France, ²²Service de Médecine interne, Hôpital Louis Mourier, AP-HP, Colombes, France, ²³Centre for Research in Epidemiology and Statistics (CRESS) and Centre d'Epidémiologie Clinique, Hôtel-Dieu Hospital, Paris, Ile-de-France, France
Background/Purpose: The management of giant cell arteritis (GCA) has evolved with the arrival of tocilizumab (TCZ) and the use of PET/CT. In modern era, a…
Abstract Number: 0337 • ACR Convergence 2024
Characterization of Statin Induced Myopathy in the Hospital Setting
Olivia Yang¹, KUMAR VENKAT², Jeffery Durbin³ and Scott Kubomoto¹, ¹Riverside Community Hospital, Riverside, CA, ²Voluntary Clinical Associate Professor of Medicine -UCRSOM, Riverside, California, IRVINE, CA, ³HCA Healthcare Physicians Services Group, Brentwood, TN
Background/Purpose: Adverse effects of statin use involve the muscle and related rhabdomyolysis. Known risk factors for rhabdomyolysis include female sex, older age, Asian race, hypothyroidism,…
Abstract Number: 0843 • ACR Convergence 2024
External Validation and Extension of Population-Based Systemic Lupus Erythematosus Risk Prediction Models Using Genetics, and Lifestyle and Environmental Factors
Jacob J.E. Koopman¹, Jing Cui¹, Hongshu Guan¹, Emma Stevens¹, Emily Oakes¹ and Karen Costenbader², ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: Many genetic and environmental risk factors for SLE are now known. We have developed SLE risk prediction models, incorporating known genetic, lifestyle, and environmental…
Abstract Number: 1390 • ACR Convergence 2024
One-year Real World Evidence Outcomes from the Cohort RADIUS (Real-world Analysis of Upadacitinib in Rheumatoid Arthritis Patients for Improved Understanding and Safety)
Luis Gomez-Lechon Quiros¹, José Miguel Sequí-Sabater², Amalia Rueda³, Costas Torrijo Nerea⁴, Carlos Valera-Ribera⁵, Juan Miguel López-Gómez⁶ and Antonio Alvarez-Cienfuegos⁷, ¹Hospital Francesc de Borja, Valéncia, Spain, ²La Ribera University Hospital, Rheumatology Department, Gandía, Comunidad Valenciana, Spain, ³Hospital General de Valencia, VALENCIA, Comunidad Valenciana, Spain, ⁴Generalitat valenciana, Valencia, Spain, ⁵Hospital Doctor Peset, Valéncia, Comunidad Valenciana, Spain, ⁶Conselleria de Sanitat/Hospital Universitario de Elda, Elda, Comunidad Valenciana, Spain, ⁷Conselleria de Sanitat/Hospital de la Vega Baja, Orihuela, Comunidad Valenciana, Spain
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory disease that affects the joints and other parts of the musculoskeletal system. Early diagnosis and initiation of…
Abstract Number: 2203 • ACR Convergence 2024
The Association of Autoantibodies with Clinical Manifestations and Long-term Outcomes in Juvenile- and Adult-onset Systemic Sclerosis
Hideaki Tsuji¹, Ryosuke Hiwa¹, Mirei Shirakashi², Shuji Akizuki³, Ran Nakashima¹, Akira Onishi⁴, Hajime Yoshifuji¹, Masao Tanaka⁴ and Akio Morinobu⁵, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, ³Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto City, Japan, ⁴Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁵Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: Our aim is to explore whether clinical features and long-term outcomes depend on autoantibodies in juvenile- and adult-onset systemic sclerosis (SSc), since they were…
Abstract Number: 2693 • ACR Convergence 2024
Risk Factors for Relapse in ANCA-Associated Vasculitis Among Patients with Relapse After Induction of Remission with Rituximab
Ellen Romich¹, Joshua Baker², Ian Green², Rennie Rhee², Carol McAlear², Ulrich Specks³, Rona Smith⁴, David Jayne⁴ and Peter Merkel², and the RITAZAREM Investigators, ¹University of Pennsylvania, Media, PA, ²University of Pennsylvania, Philadelphia, PA, ³Mayo Clinic, Rochester, MN, ⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Relapses are common in ANCA-associated vasculitis (AAV), both i) during maintenance treatment after induction of remission, and ii) after immunosuppressive treatment is discontinued. Relapses…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.